#	Pagina
attuale pagina	/open-h2020/projects/220737/index.html

Opendata, web and dolomites

ESCulab SIGNED

European Screening Centre; Unique Library for Attractive Biology

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

ESCulab project word cloud

Explore the words cloud of the ESCulab project. It provides you a very rough idea of what is the project "ESCulab" about.

insights chemical paid building investors bridging translated benefit sustainable facilities crowdsourcing 185 foundations starting phenotypes esculab collected discovery industry members off sooner medicines ultimately drug grade phenotypic quality proposition de additions lists basic patients elf biological assays accommodate externally fundamental expand supporting gap ideas data legacy maximum stimulate scientific academics model point collaborative larger curated screens risked attract innovators additonal collection 15 factory points 18 qhls screening translation qualified library compounds period expertise delivering innovative smes developers business hit suitable shoulders compound sustainability charities 550 successfully

Project "ESCulab" data sheet

The following table provides information about the project.

Coordinator	STICHTING LYGATURE Organization address address: JAARBEURSPLEIN 6 city: UTRECHT postcode: 3521 AL website: http://www.lygature.org/ contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Netherlands [NL]
Total cost	36˙729˙319 €
EC max contribution	18˙249˙992 € (50%)
Programme	1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
Code Call	H2020-JTI-IMI2-2017-12-two-stage
Funding Scheme	IMI2-RIA
Starting year	2018
Duration (year-month-day)	from 2018-12-01 to 2023-11-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	STICHTING LYGATURE STICHTING LYGATURE Organization address address: JAARBEURSPLEIN 6 city: UTRECHT postcode: 3521 AL website: http://www.lygature.org/ contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (UTRECHT)	coordinator	1˙434˙943.00
2	PIVOT PARK SCREENING CENTRE BV PIVOT PARK SCREENING CENTRE BV Organization address address: KLOOSTERSTRAAT 9 city: OSS postcode: 5349 AB website: www.lifesciencespark.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (OSS)	participant	7˙128˙756.00
3	BIOASCENT DISCOVERY LIMITED BIOASCENT DISCOVERY LIMITED Organization address address: BO NESS ROAD city: NEWHOUSE postcode: ML1 5UH website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (NEWHOUSE)	participant	6˙475˙450.00
4	UNIVERSITY OF DUNDEE UNIVERSITY OF DUNDEE Organization address address: Nethergate city: DUNDEE postcode: DD1 4HN website: www.dundee.ac.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (DUNDEE)	participant	1˙256˙612.00
5	THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD Organization address address: WELLINGTON SQUARE UNIVERSITY OFFICES city: OXFORD postcode: OX1 2JD website: www.ox.ac.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (OXFORD)	participant	491˙230.00
6	EDELRIS SAS EDELRIS SAS Organization address address: AVENUE LACASSAGNE 115 city: LYON postcode: 69003 website: www.edelris.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (LYON)	participant	292˙600.00
7	SYGNATURE DISCOVERY LIMITED SYGNATURE DISCOVERY LIMITED Organization address address: PENNYFOOT STREET BIOCITY city: NOTTINGHAM postcode: NG1 1GF website: www.sygnaturediscovery.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (NOTTINGHAM)	participant	292˙600.00
8	SYNCOM BV SYNCOM BV Organization address address: KADIJK 3 city: GRONINGEN postcode: 9747 AT website: www.syncom.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (GRONINGEN)	participant	292˙600.00
9	TAROS CHEMICALS GMBH & CO KG TAROS CHEMICALS GMBH & CO KG Organization address address: Emil-Figge-Str. 76A city: Dortmund postcode: 44227 website: www.taros.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (Dortmund)	participant	292˙600.00
10	MERCATORIAL BV MERCATORIAL BV Organization address address: KERKENBOS 1013 city: NIJMEGEN postcode: 6546 BB website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (NIJMEGEN)	participant	265˙243.00
11	MERCALEADS BV MERCALEADS BV Organization address address: KERKENBOS 1013 city: NIJMEGEN postcode: 6546 BB website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (NIJMEGEN)	participant	27˙356.00
12	ASTRAZENECA AB ASTRAZENECA AB Organization address address: Vastra Maelarhamnen city: SODERTAELJE postcode: 151 85 website: www.astrazeneca.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	SE (SODERTAELJE)	participant	0.00
13	BAYER AKTIENGESELLSCHAFT BAYER AKTIENGESELLSCHAFT Organization address address: KAISER-WILHEM-ALLEE 1 city: Leverkusen postcode: 51373 website: http://pharma.bayer.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (Leverkusen)	participant	0.00
14	GRUNENTHAL GMBH GRUNENTHAL GMBH Organization address address: ZIEGLERSTRASSE 6 city: AACHEN postcode: 52078 website: www.grunenthal.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (AACHEN)	participant	0.00
15	INSTITUT DE RECHERCHES SERVIER INSTITUT DE RECHERCHES SERVIER Organization address address: 3 Rue de la Republique city: SURESNES postcode: 92150 website: www.servier.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (SURESNES)	participant	0.00
16	JANSSEN PHARMACEUTICA NV JANSSEN PHARMACEUTICA NV Organization address address: TURNHOUTSEWEG 30 city: BEERSE postcode: 2340 website: www.janssenpharmaceutica.be contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BE (BEERSE)	participant	0.00
17	Medicines for Malaria Venture Medicines for Malaria Venture Organization address address: ROUTE DE PRE BOIS 20 ICC BUILDING BLOCK G 20 city: GENEVE postcode: 1215 website: www.mmv.org contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	CH (GENEVE)	participant	0.00
18	MERCK KOMMANDITGESELLSCHAFT AUF AKTIEN MERCK KOMMANDITGESELLSCHAFT AUF AKTIEN Organization address address: FRANKFURTER STRASSE 250 city: DARMSTADT postcode: 64293 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (DARMSTADT)	participant	0.00
19	SANOFI-AVENTIS DEUTSCHLAND GMBH SANOFI-AVENTIS DEUTSCHLAND GMBH Organization address address: BRUNINGSTRASSE 50 city: FRANKFURT AM MAIN postcode: 65929 website: www.sanofi.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (FRANKFURT AM MAIN)	participant	0.00
20	UCB BIOPHARMA SRL UCB BIOPHARMA SRL Organization address address: ALLEE DE LA RECHERCHE 60 city: BRUXELLES postcode: 1070 website: www.ucb.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BE (BRUXELLES)	participant	0.00

Map

Project objective

By bridging an important gap between basic research and drug development, ESCulab will facilitate the translation of fundamental scientific insights into innovative drug starting points. New biological ideas will be collected by crowdsourcing, novel targets, phenotypes and pathways translated and de-risked by delivering high-quality chemical starting points for drug development. Innovators from EU academics and SMEs are offered access to state-of-the-art industry-grade facilities, drug discovery expertise, and a top-quality, curated library with over 550,000 unique compounds suitable for screening potential drug targets. The ESCulab drug discovery data generated will allow the innovators to build a proposition that is likely to attract investors and/or drug developers and stimulate them to further exploit these findings. Ultimately, this will result in novel medicines – based on basic scientific findings – that will help patients (sooner).

ESCulab will achieve this by starting off the shoulders of the European Lead Factory (ELF), where this principle has been successfully implemented. 15 out of the 18 ESCulab consortium members were involved in ELF, thus ensuring maximum benefit from the ELF legacy. ESCulab will expand and enhance ELF by supporting 185 new screens. Important additions include the application of a much larger compound collection for screening, the ability to accommodate the more complex phenotypic screening assays, and the building of a sustainable business model to ensure access to Collaborative Drug Discovery activities beyond the funding period. The delivery of qualified hit lists (QHLs) is the end point for this project, but during the funding period, ESCulab will attract additonal funding for externally paid screens and hit-to-lead projects for organizations such as charities and foundations for long term sustainability of the initiative.

Deliverables

List of deliverables.
Report on the establishment of an Ethics Advisory Board	Documents, reports	2020-04-02 08:51:33
Report on the establishment of a secure IT platform for sharing project documents	Documents, reports	2020-03-27 11:47:40
Report on delivery of 1st screening sets to all 10 screening centres	Documents, reports	2020-03-27 11:45:30
Report on the establishment of a Legal and IP committee	Documents, reports	2020-03-27 11:47:33
Report on the HDB implementation for HCS	Documents, reports	2020-03-27 11:47:49
Report on established Sharepoint environment for secure data sharing outside the HDB	Documents, reports	2020-03-27 11:47:57
Report on application process being operational	Documents, reports	2020-03-27 11:47:14
Annual update on communication and dissemination activities (1)	Documents, reports	2020-03-27 11:45:49
Annual report on recruitment activities and number of submitted proposals (1)	Documents, reports	2020-03-27 11:45:06
Annual report on project output and post-QHL processes (1)	Documents, reports	2020-03-27 11:46:30
Project website established	Websites, patent fillings, videos etc.	2020-03-27 11:46:36
Report on the HDB implementation for HTS at all ESCulab screening centres	Documents, reports	2020-03-27 11:44:57
Report on the created communication and recruitment material	Documents, reports	2020-03-27 11:46:20
Annual update on the programme portfolio statistics (1)	Documents, reports	2020-03-27 11:46:07
Report on implementation of recruitment plan at 3 regional/national life science organizations	Documents, reports	2020-03-27 11:45:22

Take a look to the deliverables list in detail: detailed list of ESCulab deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ESCULAB" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ESCULAB" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

RespiriTB (2019)

Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors